Tiziana Life Sciences (TILS)


Latest News

Tiziana converts loan notes to shares

Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) h...

Conversion of outstanding loan notes

RNS Number: 0883O Tiziana Life Sciences PLC 16 August 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Conversion of outstanding loan notes, amendment of warrant terms and issue of equity London, August 16, 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and aut...

Publication of Research Article on Foralumab

RNS Number: 3714M Tiziana Life Sciences PLC 28 July 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases Foralumab (NI-0401) is a unique oral therapy that stimulates the gut immune system and ...

Tiziana enrols first patient in Phase IIa clinical trial

Tiziana Life Sciences announced the enrolment of the first patient in its Phase IIa clinical trial with milciclib, a novel inhib...

All News

16-08-17Tiziana converts loan notes to sharesStockMarketWire
16-08-17Conversion of outstanding loan notesRNS
28-07-17Publication of Research Article on ForalumabRNS
19-07-17Tiziana enrols first patient in Phase IIa clinical trialStockMarketWire
19-07-17Initiation of a Phase IIa Clinical TrialRNS
12-07-17Proposed changes to CLNs and Warrant TermsRNS
29-06-17Result of AGMRNS
12-06-17Appointment of Dr Kunwar Shailubhai as CEORNS
08-06-17Bcl-3 pre-clinical update and Director's dealingRNS
01-06-172016 Annual Report and Accounts and notice of AGMRNS
23-05-17Financial Results for Year Ended 31 December 2016RNS
24-04-17Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3pStockMarketWire
24-04-17TILS confirms Phase II clinical trial protocol for Milciclib StockMarketWire
24-04-17Announces Approval of a Phase II Clinical TrialRNS
21-04-17Announces Publication of Milciclib Clinical TrialRNS
24-03-17Tiziana Life Sciences notes exercise of warrantsStockMarketWire
24-03-17Exercise of Warrants & Issue of EquityRNS
14-03-17Arun Sanyal appointed to Scientific Advisory BoardRNS
16-01-17Warrant Expiry - ReminderRNS
03-01-17Tiziana Life Sciences in-licences NI-1201StockMarketWire
03-01-17Tiziana Life Sciences in-licenses NI-1201RNS
16-11-16Tiziana announces new data with ForalumabStockMarketWire
16-11-16New Data with ForalumabRNS
07-11-16Tiziana CFO awarded options StockMarketWire
07-11-16Grant of optionsRNS
29-09-16Half-year ReportRNS
15-09-16Confirmation of Capital ReductionRNS
18-08-16Change of Registered OfficeRNS
18-07-16Tiziana acquires a unique bio-repositoryStockMarketWire
18-07-16Tiziana acquires a unique bio-repositoryRNS
30-06-16Result of AGMRNS
29-06-16Issue of EquityRNS
10-06-16Grant of options and realisation bonusRNS
07-06-16Tiziana Life Sciences widens FY pretax lossStockMarketWire
07-06-16Final ResultsRNS
01-06-16Partnership with Cardiff Researchers Wins AwardRNS
19-05-16Journal review of anti - CD3 monoclonal antibodiesRNS
04-05-16Appointment of Dr. Robert EvansRNS
28-04-16Exercise of Warrants & Issue of EquityRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory